Key takeaways
- Tesamorelin is a growth-hormone-releasing hormone (GHRH) analog and is FDA-approved (as Egrifta) for reducing excess abdominal fat in people with HIV-associated lipodystrophy.
- Randomized controlled trials in HIV populations have shown reductions in visceral fat and liver fat, with one trial reporting limited progression of liver fibrosis.
- Uses beyond HIV-associated lipodystrophy, including for cognition, remain investigational and have not been established in large general-population trials.
- It works indirectly by prompting the body's own pituitary to release growth hormone, rather than supplying growth hormone directly.
- Any consideration of tesamorelin should involve a licensed physician who can assess whether it is appropriate and lawful for an individual.
What is tesamorelin?
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH), a naturally occurring signaling molecule. It is given by subcutaneous injection and is best known under the brand name Egrifta. In the United States it holds FDA approval for a specific, narrow purpose: reducing excess visceral (deep abdominal) fat in adults living with HIV who have lipodystrophy, a condition in which fat accumulates abnormally around the organs.
That regulatory status matters. While tesamorelin is an approved medicine for HIV-associated fat accumulation, every other application discussed in research, including liver and cognitive uses, is still considered investigational and is not an approved indication. This article is educational only and is not medical advice or a treatment recommendation.
How it works
Unlike taking growth hormone directly, tesamorelin acts further upstream. As a GHRH analog, it binds to receptors in the pituitary gland and prompts the body to release its own growth hormone in a more natural, pulsatile pattern. The downstream effects on fat tissue are thought to follow from this restored growth-hormone signaling.
This indirect mechanism is part of why researchers have been interested in tesamorelin for visceral fat specifically. Deep abdominal and liver fat are metabolically active and associated with broader health risk, and the trials below were designed around measuring those depots directly rather than overall weight.
What the research shows
The strongest evidence sits in the HIV population. A 2014 randomized controlled trial published in JAMA studied tesamorelin in people with HIV and abdominal fat accumulation, and reported reductions in both visceral adipose tissue and liver fat. Because it was randomized and controlled, this is a relatively high-quality study design, though the findings apply to that specific patient group.
A 2019 randomized, multicentre trial in The Lancet HIV looked more closely at non-alcoholic fatty liver disease (NAFLD) in people with HIV. It found reduced liver fat and limited progression of liver fibrosis. Again, this is solid randomized evidence, but within a defined HIV-affected population rather than the general public.
More recently, a 2025 phase 2 clinical trial in The Journal of Infectious Diseases explored tesamorelin for neurocognitive impairment in people with HIV and abdominal obesity. Phase 2 trials are earlier-stage and exploratory; they are designed to probe a signal, not to confirm benefit. So while the cognitive question is interesting, it remains early research and is not established.
What it is being explored for, and who it may suit
The clearest, approved use of tesamorelin is reducing excess visceral fat in HIV-associated lipodystrophy. Beyond that, the research themes that recur are liver fat and fibrosis, and, more tentatively, cognition. It is important to be honest that these adjacent uses have largely been studied within HIV populations and have not been validated in large trials of people without HIV.
That means anyone outside the approved indication should view tesamorelin as investigational. Whether it is appropriate, lawful, and sensible for a given person depends heavily on their individual medical picture, and that is a judgment only a licensed physician can make after proper assessment.
How Strong Craft Regen approaches tesamorelin
Strong Craft Regen is a coordination and education service, not a clinic. We help people understand the evidence behind compounds like tesamorelin and, where appropriate, coordinate care delivered by licensed physicians at Innovita Clinic in Vilnius, Lithuania. We do not prescribe, dose, or recommend treatment ourselves.
Our role is to make sure any conversation about tesamorelin starts with honest evidence and runs through proper physician oversight, including review of whether it is suitable and lawful in your situation. If you want to understand whether tesamorelin or another approach fits your goals, you can book a call with us, and we will help you take the next step responsibly.
The evidence
Selected peer-reviewed references, each verified against PubMed. Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Tesamorelin is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.